RINVOQ LQ vs TOFACITINIB CITRATE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. RINVOQ LQ and TOFACITINIB CITRATE are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	RINVOQ LQ	TOFACITINIB CITRATE
Rating	72/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	UPADACITINIB	TOFACITINIB CITRATE
Manufacturer	Abbvie	Somerset Theraps LLC
Dosage forms	Solution	Tablet, extended release
Drug class	Janus Kinase Inhibitor	Janus Kinase Inhibitor
Boxed warning	Boxed warning	Boxed warning
Half-life	about 8 to 14 hours (mean terminal elimination half-life)	—
Treats	Rheumatoid Arthritis	Rheumatoid Arthritis

rinvoq lq tofacitinib citrate

Rating

72/100

New

Pharmacy pays

—

Type

Active ingredient

UPADACITINIB

TOFACITINIB CITRATE

Manufacturer

Abbvie

Somerset Theraps LLC

Dosage forms

Solution

Tablet, extended release

Drug class

Janus Kinase Inhibitor

Boxed warning

Half-life

about 8 to 14 hours (mean terminal elimination half-life)

—

Treats

Rheumatoid Arthritis

Frequently asked questions

What is the difference between Rinvoq Lq and Tofacitinib Citrate?

Rinvoq Lq contains Upadacitinib, while Tofacitinib Citrate contains Tofacitinib Citrate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.